¹⁸F-FDG PET-CT zur Strahlentherapie der lokalisierten follikulären Lymphome

Zusammenfassung

Das follikuläre Lymphom ist das zweithäufigste Lymphom der westlichen Welt und beinhaltet im Regelfall insbesondere in den lokalisierten Stadien auch eine (¹⁸F-FDG) PET-CT im Rahmen des Stagings. Die Einteilung nach Ann-Arbor bzw. der modifizierten Lugano-Klassifikation ermöglicht eine Einschätzung über das weitere Therapievorgehen als auch über die Prognose. Der PET-CT kommt hier eine bedeutende Rolle zu, indem sie die bildgebende Sensitivität im Vergleich zur konventionellen CT weiter stark erhöhen kann. Verschiedene Parameter dienen bei der PET-CT zur Interpretation der Befunde, wobei insbesondere der SUVmax hier eine wichtige Rolle spielt. Weitere Parameter wie metabolisches Tumorvolumen (MTV) oder Total Lesion Glycolysis (TLG) sind Gegenstand der aktuellen Forschung. Für die Strahlentherapie spielt die PET-CT eine bedeutende Rolle, da sie eine noch präzisere Erfassung des metabolisch aktiven Lymphoms ermöglichen kann. Hierdurch können Zielvolumina weiter verkleinert und so umliegende Gewebe geschont werden. Zudem wird durch die PET-CT auch die initiale Stadieneinteilung präziser und damit einhergehend auch die Prognose bzw. das Therapie-Outcome besser abschätzbar. Im Bereich der Diagnostik und Therapiesteuerung der Hodgkin-Lymphomerkrankung ist die PET-CT schon länger unverzichtbar geworden. Mit der in den letzten Jahren steigenden Verfügbarkeit ist die PET-CT heute ein immer wichtiger werdender Bestandteil sowohl in der Primärdiagnostik als auch in der Rezidivsituation bei Patienten mit follikulärem Lymphom und findet zunehmend Eingang in die aktuellen Leitlinienempfehlungen für die Non-Hodgkin Lymphome (NHL).

Abstract

Follicular lymphoma is the second most common lymphoma in the western world and usually includes (¹⁸F-FDG) PET-CT as part of staging, especially in the localized stages. The classification according to Ann-Arbor or to the modified Lugano classification enables an assessment of the further therapeutic procedure and the prognosis. PET-CT plays an important role here, as it further can greatly increase the imaging sensitivity compared to conventional CT. Various parameters are used in PET-CT to interpret the findings, with SUVmax in particular playing an important role. Further parameters such as metabolic tumor volume (MTV) or Total Lesion Glycolysis (TLG) are the subject of current research. For radiation therapy, PET-CT plays a major role, as it can enable an even more precise recording of the metabolically active lymphoma. As a result, target volumes can be further reduced and surrounding tissue can be spared. In addition, PET-CT also makes the initial staging more precise and, as a result, the prognosis and therapy outcome can be better assessed. In the field of diagnostics and therapy management of Hodgkin's lymphoma disease, PET-CT has long been indispensable. With the growing availability in recent years, PET-CT is now an increasingly important component both in primary diagnostics and in the relapse situation in patients with follicular lymphoma and is progressively being included in the current guideline recommendations for NHL.

Schlüsselwörter

PET-CT - Follikuläres Lymphom - Strahlentherapie - Zielvolumendefinition

Keywords

PET-CT - Follicular lymphoma - Radiotherapy - Target volume definition

Publication History

Article published online:
07 March 2022

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge für Patienten mit einem follikulären Lymphom,Langversion 1.0, 2020,AWMF-Registernummer: 018/033OL. Verfügbar unter (Stand 04.06.2021): https://www.leitlinienprogramm-onkologie.de/leitlinien/follikulaeres-lymphom/
• 2 Boellaard R, Delgado-Bolton R, Oyen WJG. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354
• 3 Carbone PP, Kaplan HS, Musshoff K. et al. Report of the Committee on Hodgkinʼs Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
• 4 König L, Herfarth K, Hörner-Rieber J. et al. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlenther Onkol 2020; 196: 705-714
• 5 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390
• 6 Brady JL, Binkley MS, Hajj C. et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood 2019; 133: 237-245
• 7 Solal-Céligny P, Roy P, Colombat P. et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265
• 8 Tobin JWD, Rule G, Colvin K. et al. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Adv 2019; 3: 2804-2811
• 9 Eich HT, Heimann M, Stützer H. et al. Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy. Strahlenther Onkol 2009; 185: 288-295
• 10 Dreyling M, Ghielmini M, Rule S. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v83-v90
• 11 Wirth A, Foo M, Seymour JF. et al. Impact of 18f fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008; 71: 213-219
• 12 Cheson BD, Fisher RI, Barrington SF. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
• 13 Weiler-Sagie M, Bushelev O, Epelbaum R. et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51: 25-30
• 14 Karam M, Novak L, Cyriac J. et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107: 175-183
• 15 Le Dortz L, de Guibert S, Bayat S. et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 2307-2314
• 16 Barrington SF, Mikhaeel NG, Kostakoglu L. et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048-3058
• 17 Luminari S, Biasoli I, Arcaini L. et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013; 24: 2108-2112
• 18 Metser U, Dudebout J, Baetz T. et al. 18 F-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study. Cancer 2017; 123: 2860-2866
• 19 Janikova A, Bolcak K, Pavlik T. et al. Value of 18Ffluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?. Clin Lymphoma Myeloma 2008; 8: 287-293
• 20 Younes A, Hilden P, Coiffier B. et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28: 1436-1447
• 21 Stuschke M, Hoederath A, Sack H. et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-frühe Stadien. Cancer 1997; 80: 2273-2284
• 22 Mikhaeel NG, Milgrom SA, Terezakis S. et al. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2019; 104: 501-512
• 23 Witzens-Harig M, Hensel M, Unterhalt M. et al. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 2011; 11: 87
• 24 Herfarth K, Borchmann P, Schnaidt S. et al. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. Hemasphere 2018; 2: e160
• 25 Illidge T, Specht L, Yahalom J. et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2014; 89: 49-58
• 26 Wirth A, Mikhaeel NG, Aleman BMP. et al. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys 2020; 107: 909-933
• 27 MacManus M, Nestle U, Rosenzweig KE. et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; 91: 85-94
• 28 Thorwarth D, Beyer T, Boellaard R. et al. Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches. Nuklearmedizin 2012; 51: 140-153
• 29 Friedberg JW, Taylor MD, Cerhan JR. et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-1208
• 30 Vargo JA, Gill BS, Balasubramani GK. et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?. Cancer 2015; 121: 3325-3334
• 31 Prieto Prieto JC, Vallejo Casas JA, Hatzimichael E. et al. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. Ann Nucl Med 2020; 34: 707-717
• 32 Lowry L, Smith P, Qian W. et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86-92
• 33 Hoskin PJ, Kirkwood AA, Popova B. et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 457-463
• 34 König L, Dreyling M, Dürig J. et al. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial. Trials 2019; 20: 544
• 35 Nakajima R, Moskowitz AJ, Michaud L. et al. Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv 2020; 4: 1812-1823